Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova share news and announcements
1,152 announcements, routine notices left out, newest first. Page 20 of 24.
Nov 2010
11 Nov · Management
Mr. Arabinda Ray, an Independent Director of the Company has resigned from the Board with effect from November 11, 2010.11 Nov · Updates
11 Nov · Results
Consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 98758 lacs for quarter ending on 30-SEP-2010 against Rs. 93311 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 8209 lacs for the quarter ending on 30-SEP-2010 against Rs. 5768 lacs for the quarter ending on 30-SEP-2009.11 Nov · Results
Standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 66904 lacs for quarter ending on 30-SEP-2010 against Rs. 62736 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 9785 lacs for the quarter ending on 30-SEP-2010 against Rs. 5549 lacs for the quarter ending on 30-SEP-2009.8 Nov · Business
Hon'ble High Court of Judicature at Allahabad vide order dated October 28, 2010 received on November 02, 2010, has sanctioned the Scheme of Amalgamation & Demerger between Jubilant Life Sciences Limited (formerly Jubilant Organosys Limited); Specially Molecules Limited, Pace Marketing Specialities Limited & Jubilant Industries Limited. The company is awaiting Hon'ble High Court's Order in Form No.42 and will thereafter file certified copies of both Orders with Registrar of Companies. the Effective Date of the Scheme will be the date on which the said copies of the Orders are filed with the Registrar of Companies.3 Nov · Board meeting
To Inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2010.
Oct 2010
18 Oct · Board Meeting Deferred
Meeting of the Board of Directors of the Company which was scheduled to be held on October 20, 2010, inter-alia to consider Unaudited Financial Results of the Company for the quarter ended September 30, 2010, has been postponed.14 Oct · Company Name Change
Members of the Exchange are hereby informed that the name of Jubilant Organosys Limited shall be changed to Jubilant Life Sciences Limited w.e.f. October 20, 2010.12 Oct · Board meeting
To Inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2010.
Sep 2010
28 Sep · Business
Following meetings were held on September 24, 2010 as per the Order of the Hon'ble High Court of Judicature at Allahabad: (1) Equity Shareholders of Jubilant Organosys Limited; (2) Secured Creditors of Jubilant Organosys Limited; (3) Unsecured Creditors of Jubilant Organosys Limited; (4) Unsecured Creditors of Speciality Molecules Limited; and (5) Equity Shareholders of Pace Marketing Specialities Limited. In the above meetings the Equity Shareholders/Creditors have approved the Scheme of Amalgamation and Demerger among Jubilant Organosys Limited, Speciality Molecules Limited, Pace Marketing Specialities Limited and Jubilant Industries Limited under sections 391/394 of the Companies Act, 1956.14 Sep · Disclosure
By a Resolution by Circulation dated September 13, 2010 the Compensation Committee of the Board of Directors has approved transfer by Jubliant Employees Welfare Trust to the option holders 3,19,605 equity shares of Re.1 each on exercise of 63,921 options, as per details below : Rs.201.33 per share for 3,17,205 equity shares; Rs.258.25 per share for 1,800 equity shares and; Rs.309.00 per share for 600 Shares.3 Sep · Meeting
Annual General Meeting of the Company will be held on September 28, 2010. Further the Register of Members/Share Transfer Books of the Company will remain closed from September 21, 2010 to September 28, 2010 (both days inclusive) for the purpose of Annual General Meeting and payment of dividend.
Aug 2010
Jul 2010
30 Jul · Management
Mr. Rahul Yadav, Nominee Director of Citicorp International Finance Corporation and HPC (Mauritius) Limited, has resigned from the Board with effect from July 07, 2010. Consequently, Mr Vishal Marwaha has also ceased to be Alternate Director to Mr. Rahul Yadav.27 Jul · Disclosure
At a meeting of the Compensation Committee of the Board of Directors held on July 27, 2010, pursuant to exercise of 32,842 options, the Committee has approved transfer by Jubilant Employees Welfare Trust to the option holders, of equity shares of Re. 1 each at an exercise price of Rs. 201.33 per share for 145,010 equity shares and Rs. 258.25 per share for 19,200 equity shares.27 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 98151 lacs for quarter ending on 30-JUN-2010 against Rs. 89636 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 6273 lacs for the quarter ending on 30-JUN-2010 against Rs. 12582 lacs for the quarter ending on 30-JUN-2009.27 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 68271 lacs for quarter ending on 30-JUN-2010 against Rs. 60594 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 8019 lacs for the quarter ending on 30-JUN-2010 against Rs. 14503 lacs for the quarter ending on 30-JUN-2009.19 Jul · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2010.7 Jul · Management
Mr. Rahul Yadav, Nominee Director of Citicorp International Finance Corporation and HPC (Mauritius) Limited, has resigned from the Board with effect from July 07, 2010. Consequently, Mr Vishal Marwaha has also ceased to be Alternate Director to Mr. Rahul Yadav.
May 2010
11 May · Updates
10 May · Disclosure
At a Meeting of the Compensation Committee of the Board of Directors held on May 10, 2010, pursuant to exercise of 51,532 options, the Committee has approved transfer by Jubilant Employees Welfare Trust to the option holders, of equity shares of Re. 1 each at an exercise price of: (1) Rs. 201.33 per share for 2,56,860 equity shares and (2) Rs. 198.55 per share for 800 equity shares.10 May · Dividend
Board of Directors at its meeting held on May 10, 2010 has recommended a dividend of Rs. 2.00 per equity shares of Rs.1 amounting to Rs.3703 Lacs, subject to approval in the annual general meeting.10 May · Results
Standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 60041 lacs for quarter ending on 31-MAR-2010 against Rs. 54806 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 9201 lacs for the quarter ending on 31-MAR-2010 against Rs. (1529) lacs for the quarter ending on 31-MAR-2009.10 May · Results
Standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 244620 lacs for year ending on 31-MAR-2010 against Rs. 243072 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 36310 lacs for the year ending on 31-MAR-2010 against Rs. 26074 lacs for the year ending on 31-MAR-2009.10 May · Results
Consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 99032 lacs for quarter ending on 31-MAR-2010 against Rs. 84124 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 13716 lacs for the quarter ending on 31-MAR-2010 against Rs. 1237 lacs for the quarter ending on 31-MAR-2009.10 May · Results
Consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 378127 lacs for year ending on 31-MAR-2010 against Rs. 351798 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 42146 lacs for the year ending on 31-MAR-2010 against Rs. 28318 lacs for the year ending on 31-MAR-2009.3 May · Board meeting
To inter-alia consider: (1) Audited Financial Results of the Company for the year ended March 31, 2010. (2) Recommendation of Dividend for the year ended March 31, 2010.
Apr 2010
1 Apr · Business
Vide its letter dated March 31, 2010 that "The Capital Issue Committee, a duly authorized committee of the Board of Directors of the Company (the 'Committee') had approved the price for issue of shares to Qualified Institutional Buyers, the Bid Closing Date and Placement Document in respect of such issue, the Committee at its meeting held today, has approved the allotment of 11,237,517 equity shares of Re. 1/- each at a price of Rs. 344.50 per share, aggregating to Rs. 387.13 crores to Qualified Institutional Buyers under Chapter VIII of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended, against receipt of full payment of application monies in the escrow cash account opened by the Company". A copy of resolution passed at the meeting of the Capital Issue Committee of the Board of Directors held on March 31, 20010 shall be available on the NSE website (http://www.nseindia.com) under Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2010
30 Mar · Business
Jubilant Organosys Limited had informed the Exchange that the Capital Issue Committee, a duly authorized committee of the Board of Directors of the Company, (the "Committee") had approved the Preliminary Placement Document in respect of the issue of shares to Qualified Institutional Buyers, authorized the opening of the said issue and fixed the Bid Opening Date for the same. The Company has now informed the Exchange that the Committee at its meeting held on March 29, 2010, has decided to price the issue to Qualified Institutional Buyers at Rs. 344.50 per share i.e. at a premium of Rs. 343.50 per share. The number of shares will be 11,237,517 and the aggregate issue amount will be Rs. 387.13 crores. The Committee has fixed Bid Closing Date for the said issue as March 29, 2010.26 Mar · Business
Capital Issue Committee, a duly authorised committee of the Board of Directors of the Company (the "Committee"), at its meeting held on March 25, 2010, has approved the opening of an issue of equity shares of the Company of face value Re.1 /- each to Qualified Institutional Buyers under Chapter VIII of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009. Further the copy of the Resolution passed at the meeting has been submitted to the Exchange. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Mar · Management
Mr. Shardul S. Shroff has been appointed as Additional Director of the Company with effect from March 15, 2010. He will be an independent director.